secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001651308-24-000157
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene settles BRUKINSA patent litigation; generic entry no earlier than June 15, 2037
--------------------------------------------------------------------------------

- Settlement with MSN allows generic BRUKINSA in U.S. no earlier than June 15, 2037, subject to customary accelerations.
- Composition of matter patent expiring April 2034 was not challenged by MSN in the litigation.
- Patent litigation against Sandoz also dismissed; all ANDA suits for BRUKINSA now resolved.
- Parties filed joint stipulation to dismiss; settlement submitted to FTC and DOJ for review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000157/0001651308-24-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000157/bgne-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer